Everolimus (RAD001): Orally Bioavailable mTOR Inhibitor for Cancer Research

Executive Summary: Everolimus (RAD001) is a highly selective, orally bioavailable mTOR inhibitor that functions by forming a complex with FKBP12, leading to inhibition of mTOR kinase activity and downstream effectors such as S6K1 and 4EBP (https://doi.org/10.13028/wced-4a32). The compound is validated by in vitro and in vivo studies for antiproliferative effects in diverse cancer cell lines and animal models (https://doi.org/10.13028/wced-4a32). Inhibitory concentrations in Panc-1 and ScLc cells are 50 μg/mL and 5 μg/mL, respectively, though these exceed typical therapeutic serum levels (https://www.apexbt.com/everolimus-rad001.html). Everolimus is insoluble in water but highly soluble in DMSO and ethanol at ≥47.91 mg/mL and ≥122 mg/mL, respectively. This product is widely adopted in apoptosis assays, proliferation inhibition, and translational cancer research (https://www.apexbt.com/everolimus-rad001.html).

Biological Rationale

The PI3K/Akt/mTOR pathway is a central regulator of cell growth, proliferation, and survival. Dysregulation of this pathway is implicated in the pathogenesis of many human cancers (https://doi.org/10.13028/wced-4a32). mTOR (mechanistic target of rapamycin) functions as a serine/threonine kinase with two distinct complexes: mTORC1 and mTORC2. Inhibition of mTORC1 suppresses protein synthesis by decreasing phosphorylation of S6K1 and 4EBP, leading to cell cycle arrest and reduced tumor progression. Targeting mTOR with small-molecule inhibitors such as Everolimus (RAD001) provides a rational strategy for dissecting signal transduction and evaluating anti-cancer drug responses in both basic and translational research contexts (https://www.apexbt.com/everolimus-rad001.html).

Mechanism of Action of Everolimus (RAD001)

Everolimus is a rapamycin analog that binds with high affinity to the intracellular receptor FKBP12. The resulting Everolimus-FKBP12 complex interacts with mTOR, inhibiting its kinase activity. This interaction prevents phosphorylation of downstream effectors, notably S6 ribosomal protein kinase (S6K1) and eukaryotic translation initiation factor 4E-binding protein (4EBP). Reduced phosphorylation of these proteins suppresses cap-dependent mRNA translation and cell proliferation. Cell-permeable and orally bioavailable, Everolimus displays favorable pharmacokinetics for research and preclinical models. The molecular mechanism is specific to mTORC1 inhibition; mTORC2 is less sensitive to rapalogs such as Everolimus (https://doi.org/10.13028/wced-4a32). See the Everolimus (RAD001) product page for compound specifications and handling guidelines.

Evidence & Benchmarks

• Everolimus inhibits proliferation of Panc-1 pancreatic tumor cells with an in vitro IC₅₀ of 50 μg/mL (https://www.apexbt.com/everolimus-rad001.html).
• In ScLc small cell lung carcinoma cells, Everolimus achieves an IC₅₀ of 5 μg/mL in vitro (https://www.apexbt.com/everolimus-rad001.html).
• Therapeutic serum levels of Everolimus in clinical or animal models are typically 0.005–0.01 μg/mL, much lower than in vitro IC₅₀ values (https://www.apexbt.com/everolimus-rad001.html).
• In the TgMISIIR-TAg-DR26 mouse model of ovarian cancer, Everolimus suppresses tumorigenesis in vivo (https://doi.org/10.13028/wced-4a32).
• Everolimus is soluble at ≥47.91 mg/mL in DMSO and ≥122 mg/mL in ethanol, but is insoluble in water (https://www.apexbt.com/everolimus-rad001.html).
• Stock solutions are stable for several months at ≤ –20°C in DMSO (https://www.apexbt.com/everolimus-rad001.html).
• Everolimus selectively inhibits mTORC1, with minimal direct effect on mTORC2 (https://doi.org/10.13028/wced-4a32).
• Robust apoptosis and proliferation assays in cancer research frequently employ Everolimus as a reference mTOR pathway inhibitor (https://doi.org/10.13028/wced-4a32).

This article extends the detailed workflows found in Everolimus (RAD001): mTOR Inhibitor Workflows in Cancer Research by focusing on specific quantitative benchmarks and solubility parameters.

Compared to Everolimus (RAD001): mTOR Inhibitor Workflows for Cancer, this review clarifies the molecular selectivity and storage stability of Everolimus in experimental design.

This review also updates Everolimus (RAD001): Mechanisms and Advanced Applications by integrating recent benchmarks and clinical translation data.

Applications, Limits & Misconceptions

Everolimus (RAD001) is widely adopted for:

• Apoptosis assays in cancer cell lines to quantify drug-induced cell death and proliferation arrest (https://doi.org/10.13028/wced-4a32).
• Cancer biology studies, especially for dissecting the PI3K/Akt/mTOR signaling pathway.
• Animal models of tumorigenesis, such as ovarian and renal cell carcinoma research.
• Translational studies of mTOR pathway inhibition and resistance mechanisms.
• Optimization of immunosuppressive regimens in preclinical settings.

Common Pitfalls or Misconceptions

• Everolimus is not effective in mTORC2-driven malignancies, as it primarily inhibits mTORC1.
• In vitro IC₅₀ concentrations are orders of magnitude higher than therapeutic plasma levels; direct translation to clinical dosing is not valid.
• Everolimus is insoluble in water; improper solvent use reduces experimental reproducibility.
• Long-term storage above –20°C or repeated freeze-thaw cycles can degrade compound integrity.
• Relative viability assays may conflate cytostatic and cytotoxic effects; orthogonal readouts (e.g., apoptosis markers) are needed for mechanistic clarity (https://doi.org/10.13028/wced-4a32).

Workflow Integration & Parameters

For robust experimental design, Everolimus (RAD001) should be dissolved in DMSO or ethanol to prepare concentrated stock solutions (≥47.91 mg/mL in DMSO; ≥122 mg/mL in ethanol). Working dilutions should be freshly prepared prior to use. For in vitro assays, concentrations ranging from 1 nM to 50 μg/mL are typically tested depending on cell type sensitivity and assay endpoints. Apoptosis and proliferation assays (e.g., Annexin V/PI, MTT, or cell counting) are frequently employed. In vivo studies require careful dose conversion and pharmacokinetic modeling due to significant differences between in vitro and serum concentrations. Storage at –20°C as a solid, or below –20°C for stock solutions, preserves compound stability for several months. Prompt use after dilution minimizes degradation risk. Researchers are encouraged to consult the A8169 kit documentation for validated protocols.

Conclusion & Outlook

Everolimus (RAD001) is a validated, cell-permeable mTOR inhibitor that enables precise dissection of the PI3K/Akt/mTOR pathway in cancer and signal transduction research. Its robust solubility in organic solvents, defined mechanism via FKBP12-mTOR complex formation, and well-characterized benchmarks make it a reference compound in apoptosis and proliferation assays. Proper attention to solvent use, storage, and assay design is essential for reproducibility. Future studies will likely focus on combinatorial therapies and resistance mechanisms involving mTORC1/2 cross-talk. For detailed product specifications and validated workflows, refer to the Everolimus (RAD001) product page.